“Cluster Formation” Drives India’s Sun Pharma Chief To Invest In Smaller Pharma Units
This article was originally published in PharmAsia News
Executive Summary
Sun Pharma promoter makes early investments that could yield future strategic value
You may also be interested in...
Knowledge Synergies Between Small Innovators Can Accelerate Drug Development, Experts Speak Out
SINGAPORE - It may sound too idealistic but Israel Makov, Teva's former chief executive, believes the present drought of late-stage pipeline drugs can be filled if smaller companies doing research in "silos" share their specialized insights and form single entities to develop future drugs
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.